Cardiovascular complications in acromegaly
- PMID: 15282442
Cardiovascular complications in acromegaly
Abstract
Cardiovascular morbidity and mortality are increased in acromegaly. In fact, GH and IGF-I excess induces a specific cardiomyopathy. The early stage of acromegaly is characterized by the hyperkinetic syndrome (high heart rate and increased systolic output). Frequently, concentric biventricular hypertrophy and diastolic dysfunction occur in acromegaly, leading to an impaired systolic function ending in heart failure if the disease is untreated or unsuccessfully untreated. Besides, abnormalities of cardiac rhythm and of valves have been also described in acromegaly. The coexistence of other complications, such as arterial hypertension and diabetes, aggravates the acromegalic cardiomyopathy. The suppression of GH/IGF-I following an efficacious therapy could decrease left ventricular mass and improve cardiac function. In conclusion, a careful evaluation of cardiac function, morphology and activity seems to be mandatory in acromegaly.
Similar articles
-
Acromegaly and the cardiovascular system.Neuroendocrinology. 2006;83(3-4):211-7. doi: 10.1159/000095530. Neuroendocrinology. 2006. PMID: 17047385 Review.
-
The GH-IGF-I axis and the cardiovascular system: clinical implications.Clin Endocrinol (Oxf). 2008 Sep;69(3):347-58. doi: 10.1111/j.1365-2265.2008.03292.x. Epub 2008 May 6. Clin Endocrinol (Oxf). 2008. PMID: 18462260 Review.
-
Cardiac abnormalities in acromegaly. Pathophysiology and implications for management.Treat Endocrinol. 2004;3(5):309-18. doi: 10.2165/00024677-200403050-00004. Treat Endocrinol. 2004. PMID: 15330678 Review.
-
Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.Acta Diabetol. 2009 Jun;46(2):85-95. doi: 10.1007/s00592-009-0112-9. Epub 2009 Mar 26. Acta Diabetol. 2009. PMID: 19322513 Review.
-
GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment.Clin Endocrinol (Oxf). 2008 Oct;69(4):613-20. doi: 10.1111/j.1365-2265.2008.03258.x. Epub 2008 Apr 10. Clin Endocrinol (Oxf). 2008. PMID: 18410555
Cited by
-
Assessment of cardiac autonomic functions by heart rate recovery, heart rate variability and QT dynamicity parameters in patients with acromegaly.Pituitary. 2014 Apr;17(2):163-70. doi: 10.1007/s11102-013-0482-4. Pituitary. 2014. PMID: 23553172
-
Procalcitonin can be used as a marker of premature atherosclerosis in acromegaly.Pituitary. 2012 Sep;15(3):358-64. doi: 10.1007/s11102-011-0327-y. Pituitary. 2012. PMID: 21735088
-
Filling the gap between the heart and the body in acromegaly: a case-control study.Endocrine. 2023 Feb;79(2):365-375. doi: 10.1007/s12020-022-03232-3. Epub 2022 Oct 30. Endocrine. 2023. PMID: 36309947 Free PMC article.
-
Illicit use of androgens and other hormones: recent advances.Curr Opin Endocrinol Diabetes Obes. 2012 Jun;19(3):211-9. doi: 10.1097/MED.0b013e3283524008. Curr Opin Endocrinol Diabetes Obes. 2012. PMID: 22450858 Free PMC article. Review.
-
Serum markers of cardiovascular risk in patients with acromegaly before and after six months of treatment with octreotide LAR.Pituitary. 2008;11(1):49-53. doi: 10.1007/s11102-007-0067-1. Pituitary. 2008. PMID: 17917813
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources